152 related articles for article (PubMed ID: 24164705)
1. Efficacy of an oral and tropically stable lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis.
Ibrahim F; Sivak O; Wasan EK; Bartlett K; Wasan KM
Lipids Health Dis; 2013 Oct; 12():158. PubMed ID: 24164705
[TBL] [Abstract][Full Text] [Related]
2. Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature.
Wasan KM; Sivak O; Bartlett K; Wasan EK; Gershkovich P
Drug Dev Ind Pharm; 2015; 41(9):1425-30. PubMed ID: 25170660
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis.
Ibrahim F; Gershkovich P; Sivak O; Wasan EK; Bartlett K; Wasan KM
Int J Pharm; 2012 Oct; 436(1-2):318-23. PubMed ID: 22772485
[TBL] [Abstract][Full Text] [Related]
4. Antifungal activity of oral (Tragacanth/acrylic acid) Amphotericin B carrier for systemic candidiasis: in vitro and in vivo study.
Mohamed HA; Radwan RR; Raafat AI; Ali AE
Drug Deliv Transl Res; 2018 Feb; 8(1):191-203. PubMed ID: 29280061
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis.
Santangelo R; Paderu P; Delmas G; Chen ZW; Mannino R; Zarif L; Perlin DS
Antimicrob Agents Chemother; 2000 Sep; 44(9):2356-60. PubMed ID: 10952579
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis.
Wasan KM; Conklin JS
Antimicrob Agents Chemother; 1996 Aug; 40(8):1806-10. PubMed ID: 8843285
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits.
Petraitiene R; Petraitis V; Kelaher AM; Sarafandi AA; Mickiene D; Groll AH; Sein T; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2005 May; 49(5):2084-92. PubMed ID: 15855534
[TBL] [Abstract][Full Text] [Related]
8. Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo.
Tang X; Zhu H; Sun L; Hou W; Cai S; Zhang R; Liu F
Int J Nanomedicine; 2014; 9():5403-13. PubMed ID: 25473279
[TBL] [Abstract][Full Text] [Related]
9. A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model.
Wasan EK; Gershkovich P; Zhao J; Zhu X; Werbovetz K; Tidwell RR; Clement JG; Thornton SJ; Wasan KM
PLoS Negl Trop Dis; 2010 Dec; 4(12):e913. PubMed ID: 21151883
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulator tuftsin augments anti-fungal activity of amphotericin B against experimental murine candidiasis.
Masood AK; Faisal SM; Haque W; Owais M
J Drug Target; 2002 May; 10(3):185-92. PubMed ID: 12075819
[TBL] [Abstract][Full Text] [Related]
11. In vitro cytotoxicity of two novel oral formulations of Amphotericin B (iCo-009 and iCo-010) against Candida albicans, human monocytic and kidney cell lines.
Leon CG; Lee J; Bartlett K; Gershkovich P; Wasan EK; Zhao J; Clement JG; Wasan KM
Lipids Health Dis; 2011 Aug; 10():144. PubMed ID: 21854638
[TBL] [Abstract][Full Text] [Related]
12. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.
Smith PJ; Olson JA; Constable D; Schwartz J; Proffitt RT; Adler-Moore JP
J Antimicrob Chemother; 2007 May; 59(5):941-51. PubMed ID: 17400589
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and tissue distribution of amphotericin B following oral administration of three lipid-based formulations to rats.
Ibrahim F; Gershkovich P; Sivak O; Wasan EK; Wasan KM
Drug Dev Ind Pharm; 2013 Sep; 39(9):1277-83. PubMed ID: 22989082
[TBL] [Abstract][Full Text] [Related]
14. Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model.
Sivak O; Gershkovich P; Lin M; Wasan EK; Zhao J; Owen D; Clement JG; Wasan KM
Lipids Health Dis; 2011 Aug; 10():135. PubMed ID: 21824435
[TBL] [Abstract][Full Text] [Related]
15. Fluphenazine antagonizes with fluconazole but synergizes with amphotericin B in the treatment of candidiasis.
Lu Y; Zhou Z; Mo L; Guo Q; Peng X; Hu T; Zhou X; Ren B; Xu X
Appl Microbiol Biotechnol; 2019 Aug; 103(16):6701-6709. PubMed ID: 31201451
[TBL] [Abstract][Full Text] [Related]
16. Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model.
Zarif L; Graybill JR; Perlin D; Najvar L; Bocanegra R; Mannino RJ
Antimicrob Agents Chemother; 2000 Jun; 44(6):1463-9. PubMed ID: 10817694
[TBL] [Abstract][Full Text] [Related]
17. Hamycin treatment of candidiasis in normal and diabetic rats.
Dhuley JN
FEMS Immunol Med Microbiol; 1999 Nov; 26(2):175-80. PubMed ID: 10536305
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans.
Wasan EK; Bartlett K; Gershkovich P; Sivak O; Banno B; Wong Z; Gagnon J; Gates B; Leon CG; Wasan KM
Int J Pharm; 2009 May; 372(1-2):76-84. PubMed ID: 19236839
[TBL] [Abstract][Full Text] [Related]
19. In vivo activity of a novel amphotericin B formulation with synthetic cationic bilayer fragments.
Lincopan N; Mamizuka EM; Carmona-Ribeiro AM
J Antimicrob Chemother; 2003 Sep; 52(3):412-8. PubMed ID: 12917237
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy of cilofungin, fluconazole and amphotericin B in the treatment of systemic Candida albicans infection in the neutropenic mouse.
Bannatyne RM; Cheng PC; Fong IW
Infection; 1992; 20(3):168-70. PubMed ID: 1644494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
